IDYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IDYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). IDEAYA Biosciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.28. The higher Degree of Financial Leverage, the more volatile earnings will be.
The industry rank for IDEAYA Biosciences's Degree of Financial Leverage or its related term are showing as below:
The historical data trend for IDEAYA Biosciences's Degree of Financial Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Degree of Financial Leverage | Get a 7-Day Free Trial | 0.86 | 2.31 | -0.22 | - | 0.36 |
IDEAYA Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Degree of Financial Leverage | Get a 7-Day Free Trial | 0.10 | -0.57 | 0.37 | 0.36 | 0.28 |
For the Biotechnology subindustry, IDEAYA Biosciences's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Degree of Financial Leverage distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Degree of Financial Leverage falls into.
IDEAYA Biosciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:
Degree of Financial Leverage | = | % Change in Earnings per Share (Diluted)** | / | % Change in EBIT |
= | ( -2.01 (Mar. 2024) / -1.52 (Mar. 2023) - 1 ) | / | ( -159.169 (Mar. 2024) / -74.561 (Mar. 2023) - 1 ) | |
= | 0.3224 | / | 1.1347 | |
= | 0.28*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
IDEAYA Biosciences (NAS:IDYA) Degree of Financial Leverage Explanation
Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.
The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.
Be Aware
The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.
Thank you for viewing the detailed overview of IDEAYA Biosciences's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Yujiro S Hata | director, officer: President and CEO | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Briseno Andres Ruiz | officer: See Remarks | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Jason Throne | officer: VP, General Counsel | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Paul A. Stone | officer: SVP, General Counsel | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Darrin Beaupre | officer: SVP, Chief Medical Officer | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085 |
Catherine J Mackey | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
Michael Anthony White | officer: SVP, Chief Scientific Officer | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Michael P. Dillon | officer: SVP, Chief Scientific Officer | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Susan L. Kelley | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Mark Lackner | officer: SVP, Head of Biology | C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Andrew J. Schwab | 10 percent owner, Former 10% holder | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
John D Diekman | 10 percent owner, Former 10% holder | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Scott M Rocklage | 10 percent owner, Former 10% holder | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Co-investors Iv, L.p. | 10 percent owner, Former 10% holder | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
From GuruFocus
By PRNewswire • 09-26-2023
By PRNewswire • 10-09-2023
By PRNewswire • 09-11-2023
By GuruFocus Research • 09-15-2023
By PRNewswire • 12-05-2023
By PRNewswire • 08-10-2023
By PRNewswire • 10-25-2023
By PRNewswire • 08-02-2023
By PRNewswire • 10-23-2023
By PRNewswire • 10-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.